Evidence map›Paper›PMID 23918298›Full record

ReviewInflammopharmacology2013

Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.

Arjun Muralidharan, Maree T Smith

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Observational
  5. Review
  6. Review
  7. Article
  8. Pain in the Cancer Survivor.Cancer treatment and research · 2021
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Metastatic human breast cancer to the spine produces mechanical hyperalgesia and gait deficits in rodents.The spine journal : official journal of the North American Spine Society · 2017
    Article
  14. Article
  15. Optimization andFrontiers in pharmacology · 2017
    Article
  16. Review
  17. Review
  18. Oxidized low-density lipoprotein is associated with advanced-stage prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Arjun MuralidharanCentre for Integrated Preclinical Drug Development, The University of Queensland, Level 3, Steele Building, St Lucia Campus, Brisbane, QLD, 4072, Australia.
Maree T Smith
University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) has a high propensity for metastasis to bone. Despite the availability of multiple treatment options for relief of PCa-induced bone pain (PCIBP), satisfactory relief of intractable pain in patients with advanced bony metastases is challenging for the clinicians because currently available analgesic drugs are often limited by poor efficacy and/or dose-limiting side effects. Rodent models developed in the past decade show that the pathobiology of PCIBP comprises elements of inflammatory, neuropathic and ischemic pain arising from ectopic sprouting and sensitization of sensory nerve fibres within PCa-invaded bones. In addition, at the cellular level, PCIBP is underpinned by dynamic cross talk between metastatic PCa cells, cellular components of the bone matrix, factors associated with the bone microenvironment as well as peripheral components of the somatosensory system. These insights are aligned with the clinical management of PCIBP involving use of a multimodal treatment approach comprising analgesic agents (opioids, NSAIDs), radiotherapy, radioisotopes, cancer chemotherapy agents and bisphosphonates. However, a major drawback of most rodent models of PCIBP is their short-term applicability due to ethical concerns. Thus, it has been difficult to gain insight into the mal(adaptive) neuroplastic changes occurring at multiple levels of the somatosensory system that likely contribute to intractable pain at the advanced stages of metastatic disease. Specifically, the functional responsiveness of noxious circuitry as well as the neurochemical signature of a broad array of pro-hyperalgesic mediators in the dorsal root ganglia and spinal cord of rodent models of PCIBP is relatively poorly characterized. Hence, recent work from our laboratory to develop a protocol for an optimized rat model of PCIBP will enable these knowledge gaps to be addressed as well as identification of novel targets for drug discovery programs aimed at producing new analgesics for the improved relief of intractable PCIBP.

Indexed as

Adjuvants, PharmaceuticAnalgesics, OpioidAnimalsAnti-Inflammatory Agents, Non-SteroidalBone and BonesBone NeoplasmsCombined Modality TherapyDisease Models, AnimalDrug Therapy, CombinationHumansMaleNociceptive PainPain ManagementProstatic NeoplasmsAdjuvants, PharmaceuticAnalgesics, OpioidAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID23918298
PMCPMC3779011
OpenAlexW2055774947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.